Prevention of Novel Coronavirus Disease by Hydroxychloroquine in cancer patients.

Phase 2

Recruiting

Conditions: Condition 1: COVID-19 disease. Condition 2: Acute myeloid leukemia. Condition 3: Acute lymphoblastic leukemia. Condition 4: Breast cancer. Condition 5: Colon cancer. Condition 6: Diffuse large B cell lymphoma.
Coronavirus infection, unspecified
Acute myeloblastic leukemia
Acute lymphoblastic leukemia [ALL]
Malignant neoplasm of breast
Malignant neoplasm of colon
Diffuse large B-cell lymphoma
B34.2
C92.0
C91.0

Registration Number: IRCT20200405046958N1

Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 60

Inclusion Criteria

Patients with curable Acute Lymphoblastic Leukemia
Patients with curable Acute Myeloblastic Leukemia
Patients with curable high-grade non-Hodgkin Lymphoma
Patients with curable Breast cancer
Patients with curable Colon cancer
Age higher than 15 years

Exclusion Criteria

Known sensitivity to Hydroxychloroquine
Weight lower than 35 kilograms
History of retinopathy
History of any cardiac disease
Acute respiratory tract infection in the last 2 month
Having novel Coronavirus in the first two weeks of entering the trial
Diabetes Mellitus
Immuno-suppressive disease other than cancer
Chronic pulmonary disease
Taking immuno-suppressive drugs other than cancer chemotherapy

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
COVID-19 incidence rate in cancer patients under treatment. Timepoint: Patients are examined and investigated if they become symptomatic during the 2 months of study. Method of measurement: First, a history and physical examination are performed for the symptoms of COVID-19, and if the test is positive, a computerized tomography scan of the lungs and a nucleic acid amplification test for the SARS-CoV-2 virus.

Secondary Outcome Measures